Affimed's (AFMD) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Affimed (NASDAQ:AFMD - Free Report) in a report published on Friday morning,Benzinga reports. HC Wainwright currently has a $10.00 target price on the biopharmaceutical company's stock.

Separately, Cantor Fitzgerald reissued an "overweight" rating on shares of Affimed in a research note on Monday, September 9th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $16.00.

Affimed Stock Down 4.7 %

NASDAQ AFMD traded down $0.17 during trading hours on Friday, reaching $3.48. The company's stock had a trading volume of 82,045 shares, compared to its average volume of 266,753. Affimed has a 52 week low of $2.92 and a 52 week high of $8.95. The company has a quick ratio of 2.71, a current ratio of 2.71 and a debt-to-equity ratio of 0.13. The firm has a fifty day simple moving average of $3.50 and a 200-day simple moving average of $4.54.

Affimed (NASDAQ:AFMD - Get Free Report) last issued its quarterly earnings results on Thursday, September 5th. The biopharmaceutical company reported ($1.09) EPS for the quarter, missing analysts' consensus estimates of ($1.00) by ($0.09). The business had revenue of $0.17 million for the quarter, compared to analyst estimates of $1.67 million. Affimed had a negative return on equity of 155.30% and a negative net margin of 2,922.74%. On average, equities analysts anticipate that Affimed will post -4.25 earnings per share for the current year.

Institutional Investors Weigh In On Affimed

Several institutional investors and hedge funds have recently made changes to their positions in the business. Point72 Asset Management L.P. boosted its stake in Affimed by 4.6% during the third quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company's stock worth $1,152,000 after acquiring an additional 15,108 shares in the last quarter. Intellectus Partners LLC boosted its position in shares of Affimed by 12.2% during the 3rd quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company's stock worth $317,000 after purchasing an additional 10,250 shares in the last quarter. Choreo LLC bought a new position in shares of Affimed during the 2nd quarter worth about $54,000. Finally, FMR LLC grew its stake in shares of Affimed by 30.0% in the 3rd quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company's stock valued at $59,000 after buying an additional 4,086 shares during the period. Institutional investors own 30.82% of the company's stock.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.